Hypoxia and Epigenetic Reprogramming in Cancer: A Narrative Review of Mechanisms and Therapeutic Implications
DOI:
https://doi.org/10.32007/jfacmedbaghdad3289Keywords:
Cancer progression, Cancer stem cells, Epigenetic regulation, Hypoxia, Hypoxic memory.Abstract
Background: Epigenetic mechanisms are fundamental regulators of gene expression and cell identity; their dysregulation contributes significantly to cancer initiation and pathological development. Tumor hypoxia, a prevalent characteristic of the tumor microenvironment that profoundly alters epigenetic regulation, results in promoting tumor aggressiveness, cancer stem cell maintenance, immune evasion, and therapeutic resistance.
Objectives: This narrative review summarizes current evidence regarding hypoxia-driven epigenetic reprogramming in cancer, focusing on hypoxia-inducible factors (HIFs), DNA methylation, histone modifications, chromatin remodelling, non-coding RNAs, hypoxic memory, epithelial-mesenchymal transition (EMT), cancer stem cells (CSCs) and therapeutic resistance.
Methods: A narrative review of the literature was performed using PubMed, Scopus, and Google Scholar. Peer-reviewed studies published mainly between 2015 and 2025 were evaluated according to their relevance to hypoxia-associated epigenetic mechanisms in cancer. All articles were chosen if they were relevant to the topic and added scientific value to hypoxia associated epigenetic regulation in cancer. As this was a narrative review, there were no inclusion/ exclusion criteria or a PRISMA flow diagram.
Results: Hypoxia stabilizes HIF-1a and HIF-2α, which cooperate with multiple epigenetic regulators, including DNA methyltransferases, histone-modifying enzymes, chromatin remodelling complexes, and non–coding RNAs. These interactions promote EMT, CSC maintenance, immune escape, metastasis, and resistance to chemotherapy and immunotherapy. Emerging evidence also indicates that hypoxic memory sustains epigenetic alterations after reoxygenation, contributing to persistent malignant phenotypes.
Conclusions: Epigenetic hypoxia acts as a primary driver of cancer progression and therapeutic resistance by sustaining epigenetic reprogramming and preserving cancer stemness. Although histone deacetylase inhibitors and hypomethylating agents show therapeutic potential, their inconsistent clinical efficacy necessitates the development of optimized combination and personalized treatment strategies. Consequently, further investigation into hypoxia-driven epigenetic mechanisms is essential to enhance treatment efficacy and advance precision oncology.
Received: 12 Feb. 2026,
Revised:20 June 2026,
Accepted:22 July 2026,
Published Online: August 2026
References
. Geismann C, Arlt A. Coming in the air: hypoxia meets epigenetics in pancreatic cancer. Cells. 2020;9(11):2353. https://doi.org/10.3390/cells9112353.
2. Camuzi D, De Amorim ÍSS, Pinto LFR, et al. Regulation is in the air: The relationship between hypoxia and epigenetics in cancer. Cells. 2019;8(4):300. https://doi.org/10.3390/cells8040300.
3. Shi R, Liao C, Zhang Q. Hypoxia-driven effects in cancer: Characterization, mechanisms, and therapeutic implications. Cells. 2021;10(3):678. https://doi.org/10.3390/cells10030678.
4. Heinonen IH, Boushel R, Kalliokoski KK. The circulatory and metabolic responses to hypoxia in humans with special reference to adipose tissue physiology and obesity. Front Endocrinol (Lausanne). 2016;7:116. https://doi.org/10.3389/fendo.2016.00116.
5. Li T, Mao C, Wang X, et al. Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation. J Exp Clin Cancer Res. 2020;39(1):224. https://doi.org/10.1186/s13046-020-01733-5.
6. Li H, Peng C, Zhu C, et al. Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent manner. Clin Epigenetics. 2021;13(1):18.
https://doi.org/10.1186/s13148-021-01016-6.
7. Kim I, Park JW. Hypoxia-driven epigenetic regulation in cancer progression: A focus on histone methylation and its modifying enzymes. Cancer Lett. 2020;489:41–49. https://doi.org/10.1016/j.canlet.2020.05.025.
8. Al Tameemi W, Dale TP, Al-Jumaily RMK, et al. Hypoxia-modified cancer cell metabolism. Front Cell Dev Biol. 2019;7:4. https://doi.org/10.3389/fcell.2019.00004.
9. Ma S, Zhao Y, Lee WC, et al. Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. Nat Commun. 2022;13(1):4118. https://doi.org/10.1038/s41467-022-31764-9.
10. Saman H, Raza S, Uddin S, et al. Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches. Cancers (Basel). 2020 May 6;12(5):1172. https://doi.org/10.3390/cancers12051172.
11. Ortmann BM. Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity. BMJ Oncology. 2024;3(1):e000154. https://doi.org/10.1136/bmjonc-2023-000154.
12.Vito A, El-Sayes N, Mossman K. Hypoxia-driven immune escape in the tumor microenvironment. Cells. 2020;9(4):992. https://doi.org/10.3390/cells9040992.
13. De Leon‑Oliva D, González‑Prieto P, De Castro‑Martinez P, et al. Revisiting the biological role of the Warburg effect: Evolving perspectives on cancer metabolism. Pathol Res Pract. 2025;273:156151. https://doi.org/10.1016/j.prp.2025.156151.
14. Ung CY, Correia C, Billadeau DD, et al. Manifold epigenetics: A conceptual model that guides engineering strategies to improve whole-body regenerative health. Front Cell Dev Biol. 2023;11:1122422. https://doi.org/10.3389/FCELL.2023.1122422
15. Tronick E, Hunter RG. Waddington, Dynamic Systems, and Epigenetics. Front Behav Neurosci. 2016 Jun 10;10:107. https://doi.org/10.3389/FNBEH.2016.00107.
16. Meza-Menchaca T, Albores-Medina A, Heredia-Mendez AJ, et al. Revisiting Epigenetics Fundamentals and Its Biomedical Implications. Int J Mol Sci. 2024 Jul 1;25(14):7927 https://doi.org/10.3390/IJMS25147927/S1.
17. Agarwal AP, Kumar MS. Effect of epigenetic changes in hypoxia induced factor (HIF) gene across cancer types. Gene. 2025 Jan 20;934:149047. https://doi.org/10.1016/j.gene.2024.149047.
18. Chen Z, Han F, Du Y, et al. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Sig Transduct Target Ther. 2023;8(1):70. https://doi.org/10.1038/s41392-023-01332-8
19. Lai KP, Tim Leung CC, Boncan DAT, et al. Hypoxia-induced epigenetic transgenerational miRNAs dysregulation involved in reproductive impairment of ovary. Chem Biol Interact. 2022;367. https://doi.org/10.1016/j.cbi.2022.110176.
20. Marei HE. Epigenetic regulators in cancer therapy and progression. NPJ Precis. Onc. 2025;9(1):206.
https://doi.org/10.1038/s41698-025-01003-7.
21. Gao Y, Zhang S, Zhang X, et al. Crosstalk between metabolic and epigenetic modifications during cell carcinogenesis. iScience. 2024 Dec 20;27(12):111359. https://doi.org/10.1016/J.ISCI.2024.111359.
22. Chu X, Tian W, Ning J, et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Ther. 2024 Dec 1;9(1):170. https://doi.org/10.1038/S41392-024-01851-Y.
23. He L, Qian H, seyiti A, et al. CD133+/ABCC5+ cervical cancer cells exhibit cancer stem cell properties. Heliyon. 2024 Sep 15;10(17):e37066. https://doi.org/10.1016/j.heliyon.2024.e37066.
24. Capatina AL, Malcolm JR, Stenning J, et al. Hypoxia-induced epigenetic regulation of breast cancer progression and the tumour microenvironment. Front Cell Dev Biol. 2024 Aug 30;12:1421629 https://doi.org/10.3389/FCELL.2024.1421629
25. Zhang Y, Li J, Liu J. TET methylcytosine dioxygenases in cancer: Orchestrators of pathogenesis, immunity, immunotherapy, and chemoresistance. Int Immunopharmacol. 2025 Dec 10;167:115622. https://doi.org/10.1016/J.INTIMP.2025.115622.
26. Long NA, Golla U, Sharma A, et al. Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications. Stem Cell Rev Rep. 2022 Apr 1;18(4):1211-1226. https://doi.org/10.1007/S12015-021-10308-6.
27. Pan Y, Yuan C, Zeng C, et al. Cancer stem cells and niches: challenges in immunotherapy resistance. Mol Cancer. 2025 Dec 1;24(1):52. https://doi.org/10.1186/S12943-025-02265-2.
28. Vora P, Venugopal C, Salim SK, et al. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 2020 Jun 4;26(6):832-844.e6 https://doi.org/10.1016/J.STEM.2020.04.008.
29. Pan Y, Zhang X, Wong CC, et al. Targeting cancer stem cells enhances multikinase inhibitor therapy in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma. Gut. 2025 Dec 24;0:1-15.
https://doi.org/10.1136/GUTJNL-2025-336527.
30. Tume L, Paco K, Ubidia-Incio R, et al. CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy. Gaceta Mexicana de Oncología. 2016 Jan 1;15(1):22–30. https://doi.org/10.1016/J.GAMO.2016.01.003.
31. Brugnoli F, Grassilli S, Al-Qassab Y, et al. CD133 in Breast Cancer Cells: More than a Stem Cell Marker. J Oncol. 2019;2019(1):7512632. https://doi.org/10.1155/2019/7512632
32. Sun H, Yao N, Cheng S, et al. Cancer stem-like cells directly participate in vasculogenic mimicry channels in triple-negative breast cancer. Cancer Biol Med. 2019 Apr 1;16(2):299-311. https://doi.org/10.20892/J.ISSN.20953941.2018.0209.
33. Min KJ, So KA, Ouh YT, et al. The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers. J Ovarian Res. 2012;5(1). https://doi.org/10.1186/1757-2215-5-28.
34. Kao SH, Wu KJ, Lee WH. Hypoxia, epithelial-mesenchymal transition, and tet-mediated epigenetic changes. Journal of Clinical Medicine. 2016;5(2):24. https://doi.org/10.3390/jcm5020024.
35. Tam SY, Wu VWC, Law HKW. Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancers: HIF-1α and Beyond. Frontiers in Oncology. 2020;10:486. https://doi.org/10.3389/fonc.2020.00486.
36. Maeda K, Ding Q, Yoshimitsu M, et al. CD133 Modulate HIF-1α Expression under Hypoxia in EMT Phenotype Pancreatic Cancer Stem-Like Cells. Int J Mol Sci. 2016 Jul 1;17(7):1025. https://doi.org/10.3390/IJMS17071025.
37. Hapke RY, Haake SM. Hypoxia-induced epithelial to mesenchymal transition in cancer. Cancer Lett. 2020 Sep 1;487:10-20. https://doi.org/10.1016/J.CANLET.2020.05.012.
38. Ma H, Gu Z, Wang Z. Lactate and lactylation: metabolic architects of tumor progression and metastasis. Cellular Oncology. 2026 Apr 7;49(2):66- https://doi.org/10.1007/S13402-026-01182-W.
39. Yang Q, Dang H, Liu J, et al. Hypoxia switches TET1 from being tumor-suppressive to oncogenic. Oncogene. 2023 May 12;42(20):1634-48. https://doi.org/10.1038/S41388-023-02659-W.
40. Zhuang Y, Liu K, He Q, et al. Hypoxia signaling in cancer: implications for therapeutic interventions. MedComm (Beijing). 2023;4(1):e203. https://doi.org/10.1002/mco2.203.
41. Ma C, Cheng J, Gu J, et al. Epigenetic drugs in cancer therapy: Mechanisms, immune modulation, and therapeutic applications. Mol Biomed. 2025;6(1):132. https://doi.org/10.1186/s43556-025-00373-5.
42. Han D, Li Z, Luo L, et al. Targeting hypoxia and HIF1α in triple-negative breast cancer: New insights from gene expression profiling and implications for therapy. Biology (Basel). 2024;13(8):577. https://doi.org/10.3390/biology13080577.
43. Wu W, He Y, Zhang C. Emerging targeted and multimodal therapeutic strategies in breast cancer: A comprehensive review. Breast Cancer: Targets and Therapy. 2026;18:1–28. https://doi.org/10.2147/BCTT.S575936.
44. Lamadema N, Burr S, Brewer AC. Dynamic regulation of epigenetic demethylation by oxygen availability and cellular redox. Free Radic Biol Med. 2019 Feb 1;131:282–98. https://doi.org/10.1016/J.FREERADBIOMED.2018.12.009
45. Suraweera A, O’Byrne KJ, Richard DJ. Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 2025 Mar 1;44(1):37. https://doi.org/10.1007/S10555-025-10253-7.
Creative Commons Attribution 4.0 International license..
